Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved January 1997

Specific Treatments:

seasonal allergy symptoms

Find Related Trials for The Following Conditions

General Information

Claritin, the first and only nondrowsy allergy product available in a ready-to-take, rapidly disintegrating tablet, has been approved for the treatment of seasonal allergy symptoms. The unique formulation of Claritian RediTabs enables the tablet to disintegrate almost instantly in the mouth, delivering the proven efficacy and safety benefits of regular nonsedating Claritin tablets.

Claritian RediTabs is indicated for the relief of seasonal allergy symptoms, including itchy, watery eyes; itchy palate; sneezing; and chronic idiopathic urticaria (commonly known as hives). Available by prescription in a once daily, nonsedating tablet, Claritian RediTabs can be administered to adults and children as young as 6 years of age, making it an especially appropriate alternative for children.

Clinical Results

In controlled clinical trials using the recommended dose, the incidence of the most commonly reported adverse events was comparable to placebo.